17:06 CET
CT 2 - Clinical Trials in Radiology 1
Wednesday, February 27, 10:30 - 12:00
Room: Sky High Stage
Type of session: Clinical Trials in Radiology
Moderators: V. P. Jackson (Indianapolis/US), M. Dewey (Berlin/DE)

10:30
Primary stenting of superficial femoral artery in patients with intermittent claudication has durable effects on Health-Related Quality of Life at 24 Months: results of a randomised controlled trial
H. Lindgren1, A. Gottsater2; 1Helsingborg/SE 2Malmö/SE
10:40
Discussant
T. J. Kroencke; Augsburg/DE
10:45
Ultrasound-guided vs computed tomography-guided renal mass biopsy: a prospective randomised study
h. m. farg, A. Abdelhamid, M. Zakaria, M. El-Ksas, A. El Mahdy, M. Abd El-Hameed, T. El-Diasty; Mansoura/EG
11:00
Self-compression mammography in clinical practice: a randomised clinical trial compared to standard compression mammography
V. Iotti, M. guberti, L. canovi, P. giorgi rossi, M. bertolini, R. Vacondio, P. PATTACINI; Reggio Emilia/IT
11:10
Discussant
A. Oktay; Izmir/TR
11:15
MRI vs mammography screening for high-risk women: an RCT - the influence of density and effectiveness
A. Geuzinge1, S. Saadatmand1, E. j. j. RUTGERS2, R. M. Mann3, D. de Roy van Zuidewijn4, H. Zonderland2, R. Tollenaar5, M. B. I. Lobbes6, M. Ausems7, M. van 't Riet8, M. Hooning1, I. Mares-Engelberts1, E. Luiten9, E. Heijnsdijk1, C. Verhoef1, N. Karssemeijer3, J. Oosterwijk10, I.-M. Obdeijn1, H. de Koning1, M. Tilanus-Linthorst1; 1Rotterdam/NL 2Amsterdam/NL 3Nijmegen/NL 4Leeuwarden/NL 5Leiden/NL 6Maastricht/NL 7Utrecht/NL 8Delft/NL 9Breda/NL 10Groningen/NL
11:25
Discussant
R. Schulz-Wendtland; Erlangen/DE
11:30
Variability in cancer-positive predictive value using PI-RADS v2: a multi-institutional study conducted by the SAR Prostate Cancer Disease Focused Panel (aim 2)
A. C. Westphalen1, A. B. Rosenkrantz2, C. McCulloch1, J. Anaokar3, S. arora4, N. Barashi5, J. Barentsz6, T. Bathala7, L. Bittencourt8, M. Booker9, V. Braxton4, D. Casalino5, S. Chang10, F. Coakley11, R. Dhatt12, S. C. Eberhardt13, B. Foster11, A. Froemming14, J. J. Futterer6, M. Gertner15, L. Gettle16, S. Ghai15, R. Gupta17, M. Hahn9, R. Houshyar18, C. Kim19, C. Kim20, C. Lall21, D. Margolis22, S. McRae7, A. Oto5, r. parsons3, N. Patel23, T. Polascik17, J. Starcevich13, B. Spilseth24, V. Tammisetti7, S. Taneja22, S. Verma25, C. Warlick24, A. Weinberger5, J. Yu19, R. J. Zagoria1; 1San Francisco/US 2New York City/US 3Philadelphia/US 4Nashville/US 5Chicago/US 6Nijmegen/NL 7Houston/US 8Rio de Janeiro/BR 9San Diego/US 10Vancouver/CA 11Portland/US 12Vancouver/US 13Albuquerque/US 14Rochester/US 15Toronto/CA 16Madison/US 17Durham/US 18Irvine/US 19Richmond/US 20Seoul/KR 21Orange/US 22New York/US 23Aurora/US 24Minneapolis/US 25Cincinnati/US
11:40
11:45
Role of PI-RADS v2 in clinical models: a multi-institutional study conducted by the SAR Prostate Cancer Disease Focused Panel (aim 3)
A. C. Westphalen1, A. B. Rosenkrantz2, C. McCulloch1, J. Anaokar3, S. arora4, N. Barashi5, J. Barentsz6, T. Bathala7, L. Bittencourt8, M. Booker9, V. Braxton4, D. Casalino5, S. Chang10, F. Coakley11, R. Dhatt10, S. C. Eberhardt12, B. Foster11, A. Froemming13, J. J. Futterer6, M. Gertner14, L. Gettle15, S. Ghai16, R. Gupta17, M. Hahn9, R. houshyar18, C. Kim19, C. Kim20, C. Lall18, D. Margolis21, S. McRae7, A. Oto5, r. parsons3, N. Patel22, T. Polascik17, J. Starcevich12, B. Spilseth23, V. Tammisetti7, S. Taneja21, S. Verma24, C. Warlick23, A. Weinberger5, J. Yu19, R. J. Zagoria1; 1San Francisco/US 2New York City/US 3Philadelphia/US 4Nashville/US 5Chicago/US 6Nijmegen/NL 7Houston/US 8Rio de Janeiro/BR 9San Diego/US 10Vancouver/CA 11Portland/US 12Albuquerque/US 13Rochester/US 14Toronto/CA 15Madison/US 162n2/CA 17Durham/US 18Orange/US 19Richmond/US 20Seoul/KR 21New York/US 22Aurora/US 23Minneapolis/US 24Cincinnati/US
11:55
Discussant
E. Rud; Oslo/NO
This website uses cookies. Learn more